Fosrenol Side Effects
Generic name: lanthanum carbonate
Medically reviewed by Drugs.com. Last updated on Sep 13, 2023.
Note: This document provides detailed information about Fosrenol Side Effects associated with lanthanum carbonate. Some dosage forms listed on this page may not apply specifically to the brand name Fosrenol.
Applies to lanthanum carbonate: oral powder, oral tablet chewable.
Common side effects of Fosrenol
Some side effects of lanthanum carbonate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- nausea
Incidence not known
- belching
- heartburn
- indigestion
- stomach discomfort or upset
- tooth injury
Serious side effects of Fosrenol
Along with its needed effects, lanthanum carbonate (the active ingredient contained in Fosrenol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking lanthanum carbonate:
Less common
- stomach pain
Incidence not known
- bloody, black, or tarry stools
- bone pain
- constipation, severe
- difficulty having a bowel movement
- itching, skin rash
- loss of appetite
- seizures
- severe stomach pain, cramping, or burning
- trouble breathing
- unusual tiredness or weakness
- vomiting of material that looks like coffee grounds, severe and continuous
- vomiting, severe
Get emergency help immediately if any of the following symptoms of overdose occur while taking lanthanum carbonate:
Symptoms of overdose
- headache
For healthcare professionals
Applies to lanthanum carbonate: oral powder for reconstitution, oral tablet chewable.
General
The most common adverse reactions included nausea, vomiting, and abdominal pain.[Ref]
Gastrointestinal
- Very common (10% or more): Nausea (up to 37%), vomiting (up to 27%), diarrhea (up to 24%), abdominal pain (up to 17%), constipation (up to 15%)
- Common (1% to 10%): Dyspepsia, flatulence
- Uncommon (0.1% to 1%): Gastroenteritis, eructation, indigestion, irritable bowel syndrome, dry mouth, stomatitis, loose stools, esophagitis, tooth disorder
- Postmarketing reports: Tooth injury chewing the tablet, intestinal perforation, intestinal obstruction, ileus, subileus[Ref]
Nausea, diarrhea, and vomiting occurred more frequently among patients taking the oral powder formulation than those receiving the chewable tablets (18% versus 7%).[Ref]
Metabolic
- Common (1% to 10%): Hypocalcemia
- Uncommon (0.1% to 1%): Hypercalcemia, hyperglycemia, hyperphosphatemia, hypophosphatemia, anorexia, appetite increased, thirst[Ref]
Respiratory
- Common (1% to 10%): Bronchitis, rhinitis
- Uncommon (0.1% to 1%): Laryngitis[Ref]
Endocrine
- Uncommon (0.1% to 1%): Hyperparathyroidism[Ref]
Serum parathyroid concentrations may fluctuate depending on a patient's serum calcium, phosphate and vitamin D status. This drug has not been shown to have any direct effects on PTH secretion.[Ref]
Hypersensitivity
Musculoskeletal
- Uncommon (0.1% to 1%): Arthralgia, myalgia, osteoporosis[Ref]
The effects of this drug on the bones of patients undergoing dialysis have been evaluated in studies of up to 4.5 years duration. Compared with standard treatments including calcium carbonate, no differences in adverse effects on the musculoskeletal system, including fractures, were observed.[Ref]
Dermatologic
Other
- Uncommon (0.1% to 1%): Vertigo, asthenia, fatigue, malaise[Ref]
Cardiovascular
- Uncommon (0.1% to 1%): Chest pain, peripheral edema[Ref]
Hematologic
- Uncommon (0.1% to 1%): Eosinophilia[Ref]
Nervous system
- Very common (10% or more): Headache (up to 22%)
- Uncommon (0.1% to 1%): Dizziness, taste alteration[Ref]
Renal
- Very common (10% or more): Dialysis graft occlusion (up to 25%)[Ref]
References
1. (2004) "Product Information. Fosrenol (lanthanum carbonate)." Shire US Inc
2. Cerner Multum, Inc. "Australian Product Information."
3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
More about Fosrenol (lanthanum carbonate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: phosphate binders
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Fosrenol side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.